These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 10921314)

  • 41. Genetic testing for breast cancer susceptibility: frequency of BRCA1 and BRCA2 mutations.
    Ganguly A; Leahy K; Marshall AM; Dhulipala R; Godmilow L; Ganguly T
    Genet Test; 1997; 1(2):85-90. PubMed ID: 10464631
    [TBL] [Abstract][Full Text] [Related]  

  • 42. BRCA1 and BRCA2 and breast cancer incidence: a review.
    Bishop DT
    Ann Oncol; 1999; 10 Suppl 6():113-9. PubMed ID: 10676562
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Population-based estimate of the average age-specific cumulative risk of breast cancer for a defined set of protein-truncating mutations in BRCA1 and BRCA2. Australian Breast Cancer Family Study.
    Hopper JL; Southey MC; Dite GS; Jolley DJ; Giles GG; McCredie MR; Easton DF; Venter DJ
    Cancer Epidemiol Biomarkers Prev; 1999 Sep; 8(9):741-7. PubMed ID: 10498392
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Comprehensive genetic characterization of hereditary breast/ovarian cancer families from Slovakia.
    Konecny M; Milly M; Zavodna K; Weismanova E; Gregorova J; Mlkva I; Ilencikova D; Kausitz J; Bartosova Z
    Breast Cancer Res Treat; 2011 Feb; 126(1):119-30. PubMed ID: 21203900
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Hereditary ovarian cancer in Poland.
    Menkiszak J; Gronwald J; Górski B; Jakubowska A; Huzarski T; Byrski T; Foszczyńska-Kłoda M; Haus O; Janiszewska H; Perkowska M; Brozek I; Grzybowska E; Zientek H; Góźdź S; Kozak-Klonowska B; Urbański K; Miturski R; Kowalczyk J; Pluzańska A; Niepsuj S; Koc J; Szwiec M; Drosik K; Mackiewicz A; Lamperska K; Strózyk E; Godlewski D; Stawicka M; Waśko B; Bebenek M; Rozmiarek A; Rzepka-Górska I; Narod SA; Lubiński J
    Int J Cancer; 2003 Oct; 106(6):942-5. PubMed ID: 12918074
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Double heterozygosity for mutations in the BRCA1 and BRCA2 genes in a breast cancer patient.
    Tsongalis GJ; Linfert DR; Johnson RC; Ackroyd R; Berman MM; Ricci A
    Arch Pathol Lab Med; 1998 Jun; 122(6):548-50. PubMed ID: 9625424
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Ovarian cancer associated with inherited mutations in BRCA1 or BRCA2.
    Swisher E
    Curr Womens Health Rep; 2003 Feb; 3(1):27-32. PubMed ID: 12521547
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Germline mutations of the BRCA1 and BRCA2 genes in a breast and ovarian cancer patient.
    Randall TC; Bell KA; Rebane BA; Rubin SC; Boyd J
    Gynecol Oncol; 1998 Sep; 70(3):432-4. PubMed ID: 9790802
    [TBL] [Abstract][Full Text] [Related]  

  • 49. The rate of the founder Jewish mutations in BRCA1 and BRCA2 in prostate cancer patients in Israel.
    Vazina A; Baniel J; Yaacobi Y; Shtriker A; Engelstein D; Leibovitz I; Zehavi M; Sidi AA; Ramon Y; Tischler T; Livne PM; Friedman E
    Br J Cancer; 2000 Aug; 83(4):463-6. PubMed ID: 10945492
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Multiple founder effects and geographical clustering of BRCA1 and BRCA2 families in Finland.
    Sarantaus L; Huusko P; Eerola H; Launonen V; Vehmanen P; Rapakko K; Gillanders E; Syrjäkoski K; Kainu T; Vahteristo P; Krahe R; Pääkkönen K; Hartikainen J; Blomqvist C; Löppönen T; Holli K; Ryynänen M; Bützow R; Borg A; Wasteson Arver B; Holmberg E; Mannermaa A; Kere J; Kallioniemi OP; Winqvist R; Nevanlinna H
    Eur J Hum Genet; 2000 Oct; 8(10):757-63. PubMed ID: 11039575
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Differences between hereditary and sporadic ovarian cancer.
    Zweemer RP; Verheijen RH; Menko FH; Gille JJ; van Diest PJ; Coebergh JW; Shaw PA; Jacobs IJ; Kenemans P
    Eur J Obstet Gynecol Reprod Biol; 1999 Feb; 82(2):151-3. PubMed ID: 10206407
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Inherited breast cancer: increasingly familiar territory.
    Garber J
    J Clin Oncol; 1998 May; 16(5):1639-41. PubMed ID: 9586872
    [No Abstract]   [Full Text] [Related]  

  • 53. Inherited susceptibility to breast and ovarian cancer.
    Diamond TM; Sutphen R; Tabano M; Fiorica J
    Curr Opin Obstet Gynecol; 1998 Feb; 10(1):3-8. PubMed ID: 9484622
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Hereditary and sporadic ovarian cancer: genetic testing and clinical implications (review).
    Angioli R; Estape R; Mason M; Penalver M
    Int J Oncol; 1998 May; 12(5):1029-34. PubMed ID: 9538124
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The APC I1307K allele and BRCA-associated ovarian cancer risk.
    Maresco DL; Arnold PH; Sonoda Y; Federici MG; Bogomolniy F; Rhei E; Boyd J
    Am J Hum Genet; 1999 Apr; 64(4):1228-30. PubMed ID: 10090911
    [No Abstract]   [Full Text] [Related]  

  • 56. Genetic susceptibility testing and prophylactic oophorectomy.
    Berchuck A; Carney ME; Futreal PA
    Eur J Obstet Gynecol Reprod Biol; 1999 Feb; 82(2):159-64. PubMed ID: 10206409
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Major oncogenes and tumor suppressor genes involved in epithelial ovarian cancer (review).
    Aunoble B; Sanches R; Didier E; Bignon YJ
    Int J Oncol; 2000 Mar; 16(3):567-76. PubMed ID: 10675491
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In search of the tumour-suppressor functions of BRCA1 and BRCA2.
    Scully R; Livingston DM
    Nature; 2000 Nov; 408(6811):429-32. PubMed ID: 11100717
    [TBL] [Abstract][Full Text] [Related]  

  • 59. [Hereditary ovarian cancer as a separate clinical entity].
    Majdak E; Debniak J; Emerich J
    Ginekol Pol; 2003 Jul; 74(7):557-64. PubMed ID: 14531330
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Familial ovarian malignancy.
    Crawford R; Everest S; Mackay J
    Hosp Med; 2000 Aug; 61(8):528-31. PubMed ID: 11045219
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.